Alvotech (ALVO) has released an update.
Alvotech has partnered with Advanz Pharma to commercialize two biosimilar candidates to Eylea® in Europe, aiming to provide more affordable biologic treatments for eye disorders. The deal grants Advanz Pharma exclusive rights to commercialize these biosimilars across Europe, with Alvotech handling development and supply. This collaboration is part of Alvotech’s strategy to be a global leader in biosimilars, offering cost-effective alternatives for high-demand medicines.
For further insights into ALVO stock, check out TipRanks’ Stock Analysis page.
